The purpose of this study was to compare the effects of different dose intravenous immunoglobulin for treatment of acute idiopathic thrombocytopenic purpura. Randomized controlled trials (RCTs) comparing high-dose intravenous immunoglobulin (HD-IVIG) with low-dose intravenous immunoglobulin (low-IVIG) for acute idiopathic thrombocytopenic purpura (ITP) were identified using a predefined search strategy. Effective rate, time of cessation of bleeding, time of platelet count beginning to rise, platelet count by the first week of treatment, the number of platelets after 2 weeks of treatment, time of platelet count to reach peak, peak value of platelet count after treatment, sideeffects and rate of developing into chronic ITP were extracted and compared by RevMan 4.2.8 (The Cochrane Collaboration, Oxford, UK). Thirteen RCTs (646 patients) were identified. Meta-analysis showed that effective rate, time of cessation of bleeding, time of platelet count beginning to rise, platelet count by the first week of treatment, the number of platelets after 2 weeks of treatment, time of platelet count to reach peak, peak value of platelet count after treatment and rate of developing into chronic ITP were not statistically different between the two different treatment administrations. However, low-IVIG was associated with a significantly reduced risk of side-effects {odds ratio ( Keywords: acute idiopathic thrombocytopenic purpura, high-dose intravenous immunoglobulin, low-dose intravenous immunoglobulin, meta-analysis
Introduction
Idiopathic thrombocytopenic purpura (ITP), an autoantibody-mediated disorder affecting both children and adults, is one of the most common haemostasis disorders. The majority of patients with acute ITP run a course remitting within several weeks to 6 months [1] . Options for treatment of acute ITP include steroids, intravenous immunoglobulin (IVIG), anti-D immunoglobulin and no drug therapy during past decades [2] . In most cases, the life-threatening hemorrhage is the main reason for drug therapy [2] .
Intravenous gamma globulin is widely used in clinic for treating patient suffering from ITP. Because of adverse effects of steroids and needing bone marrow aspiration before administration of steroids, IVIG is a substituted agent for steroids in recent years [2] . IVIG can induce a rapid response in platelet counts and stop bleeding quickly. However, IVIG administration brings some adverse effects such as fever, nausea, vomiting, headache, venous and arterial thrombosis [3, 4] . The reason may be that IVIG infusion elevates blood viscosity, and the increased blood viscosity can cause a hypercoagulable state [4] and leads to adverse reaction. Side reaction of high-dose intravenous immunoglobulin (HD-IVIG) is more obvious than that of low-dose intravenous immunoglobulin (low-IVIG) in clinical administration. In order to explore a suitable treatment schedule, the dosage of IVIG in ITP treatment was changed during the past decades. There was a controversy in the past about whether low-IVIG could get a similar effectiveness to HD-IVIG for the patients with ITP. Furthermore, in some developing countries, such as China and some other Asian countries, the cost of a scheme such as 0.2 g/kg per day for 5 days is much less than that of 2.0 g/kg for a single dose (cost of medication much more than infusion cost). Therefore, this meta-analysis was conducted to explore whether a low-IVIG regimen could get a similar effectiveness as HD-IVIG administration for patients with ITP.
There are some different characteristics between acute ITP and chronic ITP in the therapeutic standard strategies. Administration of IVIG is the fastest way to increase the platelet count for patients with acute ITP, but IVIG often must be repeatedly infused for chronic ITP [5] . In order to enhance the credibility of the evidence in our study, we only recruited the randomized controlled trials (RCTs) for acute ITP under treatment with immunoglobulin administration. For all the included literature, the total dose of 2 g/kg was regarded as the HD-IVIG schedule, and less than 2 g/kg was regarded as low-IVIG.
Materials and methods

Search strategy
The relevant studies were screened from the search engines of PubMed and CBM-disc (China Biological Medicine Database) as of 31 December 2009. [(idiopathic thrombocytopenic purpura or ITP) and (high-dose intravenous immunoglobulin or low-dose intravenous immunoglobulin) and [therapy/narrow (filter)] was used in PubMed without language limitation. CBM-disc was searched using the terms [(idiopathic thrombocytopenic purpura or ITP) and (high-dose intravenous immunoglobulin) or (low-dose intravenous immunoglobulin) or (intravenous immunoglobulin)]. We also extended search spectrum to the 'related articles' and the bibliographies of all retrieved studies. If multiple publications from the same study group occurred, we only recruited the most complete paper for analysis.
Inclusion and exclusion criteria
Inclusion criteria
The inclusion criteria for the study are given below:
(1) Study type: RCTs. (2) Object of the study: all patients who met the diagnostic criteria for acute ITP [6] . (3) Interventions: using low-IVIG and HD-IVIG for treatment, respectively. (4) Baseline information: comparable.
Exclusion criteria
The exclusion criteria for the study are given below:
(1) IVIG total dose of high-dose group was less than 2 g/kg or that in low-dose group was more than 2 g/kg (total dose of 2 g/kg was regarded as the high-dose for ITP patient [7] ). (2) Low-dose group or high-dose group including other drug. (3) The diagnostic criteria were not clear.
Outcome measures
Effective rate, time of cessation of bleeding, time of platelet count beginning to rise, platelet count by the first week of treatment, the number of platelets after 2 weeks of treatment, time of platelet count to reach peak, peak value of platelet count after treatment, side-effects and rate of developing into chronic ITP.
Data collection
Method of agreeing inclusion of studies was performed by two observers (Y.-H. Q., T.-B. Z.) independently according to predetermined inclusion criteria. Titles and abstracts were scanned first to make a list of possibly related literature and then full texts were obtained for those articles identified as either relevant or not clear, only RCTs fitting predefined inclusion criteria were included. Disagreements were resolved by other reviewers (L.-N. S., F.-Y. L.).
Appraising the quality of literature The Jadad scale [8] was used to score the quality of the included articles (Table 1) [9] [10] [11] [12] [13] [14] [15] [16] [17] [18] [19] [20] [21] . On the basis of scores, we subdivided them into the following two categories: the score below 3 was regarded as low quality and the 3-5 score was high quality (total score was 5). In order to get the detailed implementation process, we tried our best to contact the authors by e-mail or telephone (Y.-J. Z., W.-F. H.).
Statistical analysis
Statistical analysis was performed by RevMan 4.2.8. The pooled statistics were calculated using the fixed effect model, but a random effect model was conducted if P value of heterogeneity test was less than 0.1. Results were expressed with odds ratios (OR) for dichotomous data and weighted mean differences (WMD) for continuous data, and 95% confidence intervals (CI) were also counted.
Heterogeneity between included studies was tested using the x 2 -test. If heterogeneity was present, we would try to check the reason out from aspects of study design and quality by using the methods of subgroup and sensitivity analysis. Funnel plot was drawn to assess the publication bias in our study.
Results
The search yielded 352 references, 16 in Pubmed and 336 in CBM-disc. Finally, 15 RCTs included low-IVIG and HD-IVIG administration for ITP. One trial was excluded because the total dose of HD-IVIG group was only 1 g/kg and the type of ITP was not in detail [22] , and the patients in one study included acute ITP and chronic ITP [3] . Thirteen studies were included in our final review ( Fig. 1 ). Eleven studies were published in Chinese [10, 11, [13] [14] [15] [16] [17] [18] [19] [20] [21] and two in English [9, 12] . The data of interest were extracted: effective rate, time of cessation of bleeding, time of platelet count beginning to rise, platelet count by the first week of treatment, the number of platelets after 2 weeks of treatment, time of platelet count to reach peak, peak value of platelet count after treatment, side-effects and rate of developing into chronic ITP. These 13 studies contained 646 case series (low-IVIG 332, HD-IVIG 314) ( Table 1 ). The baseline information of the literature was comparable.
Effective rate
The curative effect evaluation criteria developed by the second session of the National Conference on Hematology in China [6] was referenced in our study: marked effectplatelet count less than 100 Â 10 9 /l for 2 months, cessation of bleeding; well effect -platelet count from 50 to 100 Â 10 9 /l for 2 months, cessation of bleeding; improvement -increasing the platelet count, improving the bleeding symptoms; invalid -no improvement of platelet and bleeding symptoms. The number of patients getting a good therapeutic effect was calculated as marked effect with well effect. Eight studies were included in our metaanalysis (469 patients) [10, [14] [15] [16] [17] [18] 20, 21] . Pooled ORs was 1.00 (95% CI 0.61-1.63). Difference of effective rate was not statistically significant between low-IVIG group and HD-IVIG group (P ¼ 1). The P value of heterogeneity test was 0.97 ( Fig. 2) .
Time of cessation of bleeding
Data of time of cessation of bleeding were extracted from five studies (218 patients) [10, 11, 13, 15, 20] , and the pooled WMD was 0.02 (95% CI À0.35 to 0.38), suggesting there was no statistical significance between the two groups (P ¼ 0.94). The test for heterogeneity was negative with a P value of 0.93 (Fig. 3) .
Time of platelet count beginning to rise
Three studies (152 patients) [13, 15, 20] reported the time of platelet count beginning to rise, and the pooled WMD was 0.04 (95% CI À0.18 to 0.27). Difference was not statistically significant between low-IVIG group and HD-IVIG group (P ¼ 0.71). The P value of the heterogeneity test was 0.89 (Fig. 4) .
Platelet count by the first week of treatment Three trials (102 patients) [14, 19, 21] were included in this analysis. Pooled WMD was À8.45 (95% CI À37.55 to 20.65), revealing there was no significant difference between low-IVIG group and HD-IVIG group (P ¼ 0.57). The test for heterogeneity was positive (P ¼ 0.67, Fig. 5 ).
The number of platelets after 2 weeks of treatment Data of three RCTs (102 patients) [14, 19, 21] were useful for meta-analysis, and the pooled WMD was À5.44 (95% CI À38.65 to 27.78), suggesting that there was no significant difference between the two groups (P ¼ 0.75). The test for heterogeneity was positive with a P value of 0.94 (Fig. 6) .
Time of platelet count to reach peak Six studies [10, [13] [14] [15] 18, 21] (273 patients), reporting the index of time of platelet count to reach peak, were Meta-analysis of IVIG for acute ITP Qin et al. 715 reviewed. Pooled WMD was 0.2 (95% CI À0.80 to 1.21).
The difference was not statistically significant between low-IVIG group and HD-IVIG group (P ¼ 0.69). The P value of the heterogeneity test was 1 (Fig. 7) .
Peak value of platelet count after treatment For the analysis of peak value of platelet count after treatment, five randomized studies [10, [13] [14] [15] 18] (223 patients) were counted. Pooled WMD was À11.46 (95% CI À44.90 to 21.97). Difference between two groups was not statistically significant (P ¼ 0.05). The test for heterogeneity was positive (P ¼ 1 Fig. 8 ).
Side-effects Data were obtained from five studies [9, 10, 12, 13, 18, 21] (334 patients) and pooled to examine the side-effects of low-IVIG treatment and HD-IVIG administration. Pooled OR was 0.39 (95% CI 0.18-0.83). The difference was markedly significant between low-IVIG group and HD-IVIG group (P ¼ 0.01). The test for heterogeneity was positive with a P value of 0.28 ( Fig. 9) .
Rate of developing into chronic idiopathic thrombocytopenic purpura
Most studies did not report whether there were some patients developing into chronic ITP, and only three studies [9, 12, 19] (129 patients) were recruited. Pooled OR was 1.62 (95% CI 0.62-4.21). Difference between low-IVIG group and HD-IVIG group was not significant (P ¼ 0.32). The P value of the heterogeneity test was 0.57 ( Fig. 10 ).
Subgroup analysis according to age or race According to age of the patients in investigations, we divided the included studies into two groups, children group and adults group. In children group, eight studies [9] [10] [11] [12] [13] 15, 16, 19] were included for our analysis, and four studies [14, 17, 20, 21] were recruited into our analysis for adults. One report [18] , including children and adults, was excluded from our subgroup analysis. Pooled ORs or WMDs in children or adults were calculated, and we found results of effective rate, time of cessation of bleeding, time of platelet count beginning to rise, platelet count by the first week of treatment, the number of platelets after 2 weeks of treatment, time of platelet count to reach peak, peak value of platelet count after treatment and rate of developing into chronic ITP in two groups were similar to the results of overall analyses. However, for the analysis of side-effects, four studies [9, 10, 12, 13] on children group and one study [21] for adults were only included. The pooled OR of side-effects suggested that there was no statistical difference between low-IVIG and HD-IVIG for children or adults (children, OR ¼ 0.53, 95% CI 0.21-1.33, P ¼ 0.17; adults, OR ¼ 0.64, 95% CI 0.10-4.19, P ¼ 0.64). However, the result was different from that of overall patients (OR ¼ 0.39, 95% CI 0.18-0.83, P ¼ 0.01).
We also conducted the subgroup analysis on the basis of race, but there were two studies [9, 12] conducted for whites and we only recruited the indicators of side-effects and rate of developing into chronic ITP from the Caucasian reports into this meta-analysis. The P value of side-effects in Asian patients was 0.02, but 0.25 for whites (Asians, OR ¼ 0.22, 95% CI 0.06-0.81; whites, OR ¼ 0.56, 95% CI 0.21-1.48), and there were four included studies [10, 13, 18, 21] for Asians. For the analysis of rate of developing into chronic ITP, there was no marked difference between low-IVIG and HD-IVIG for Asians or Caucasian patients (Asians, OR ¼ 0.31, 95% CI 0.01-8.30, P ¼ 0.48; whites, OR ¼ 1.98, 95% CI 0.71-5.56, P ¼ 0.19), and we only recruited one report [19] into our analysis for Asians. It was difficult to draw a stable conclusion. However, the result was similar to that of overall patients (OR ¼ 1.62, 95% CI 0.62-4.21, P ¼ 0.32).
Testing for publication bias A funnel plot was drawn to assess publication bias. For most indicators, there were too few studies included. We only drew funnel plot for the effective rate in our metaanalysis. Published bias existed in our study (Fig. 11 ).
Discussion
We have endeavoured to provide enough information to help physician and stakeholders choose the most appropriate treatment for patients with acute ITP. This metaanalysis might be value for the doctor to choose a suitable scheme, especially in some countries where the cost of HD-IVIG is much more than that of using low-IVIG for 1-5 days. The evidence found in this systematic review stated that effective rate, time of cessation of bleeding, time of platelet count beginning to rise, platelet count by the first week of treatment, the number of platelets after 2 weeks of treatment, time of platelet count to reach peak, peak value of platelet count after treatment and rate of developing into chronic ITP were not statistically significant between low-IVIG group and HD-IVIG group, but the side-effects in HD-IVIG administration group might be more prone to happen. This systematic review Meta-analysis of IVIG for acute ITP Qin et al. 717 , heterogeneity index; IVIG, intravenous immunoglobulin; SD, standard deviation; WMD, weighted mean differences. strongly supported that low-IVIG could get a similar efficacy as HD-IVIG and reduce the adverse effects.
Acute ITP, as one of the most common bleeding disorders, may develop into serious spontaneous bleeding when the platelet count is under 20 000/ml [2] . Intracranial haemorrhage and gastrointestinal bleeding are the most serious complications, which can jeopardize the life of patient with acute ITP in a short time [2] . Therefore, how to increase the platelet count rapidly is much important in clinical administration. In the past decades, adrenal cortex hormones was used in the treatment of acute ITP, but there were some shortcomings that the elevated platelet was instable and haemorrhage symptom was easy to recur [23] [24] [25] . As a substituted agent for steroids, IVIG can increase the platelet count rapidly and provide a positive effect to prevent the spontaneous bleeding for patient with acute ITP [23, 24] . However, the shortcoming of the IVIG regimen is that it is more expensive than other regimens and only stays in the body for a short time. During the treatment period of IVIG, the platelet count reaches the peak on the first week, begins to decline after the first week and falls to a minimum value at the third week [26] ; the plasma level of immunoglobulin (IgG) restores to its original level [27] . It seems the platelet count may be related to the plasma level of IVIG. In other words, the dosage of infused IVIG may have a positive correlation with the therapeutic effect. Seifried et al. [28] found that there existed dose-response relationship by analyzing the relation between IVIG concentration and platelet count in three patients with ITP, and time of platelet to reach peak or peak value of platelet count had a significant correlation with the concentration of IVIG in serum. On the contrary, Cohen [29] reported that low dose of IVIG had been proposed to be as effective as higher doses. Emmerich et al. [30] found that the onset and duration of response as well as the peak platelet count was independent to the doses of IVIG. If the reduced dose were as effective as high dosage, it would also reduce the cost of treatment in some developing countries such as China. In order to explore these problems, we conducted this meta-analysis. Our result showed that the differences of therapeutic effects between low-IVIG treatment administration and HD-IVIG treatment protocol were not statistically significant. The outcome predicted that the onset and duration of response of acute ITP might be independent to the plasma level of IVIG.
In our study, the indicators of time of cessation of bleeding, time of platelet count beginning to rise and time of platelet to reach peak were a little favourable to the HD-IVIG group (WMD ¼ 0.02, WMD ¼ 0.04 and WMD ¼ 0.20, respectively), although the differences were not statistically significant (P ¼ 0.94, P ¼ 0.71 and P ¼ 0.69, respectively). As we all know, these indexes are very important for preventing some serious complications such as intracranial bleeding. We speculate that the HD-IVIG regimen can improve the symptom of severe bleeding more quickly than the low-IVIG [31] and prevent some life-threatening haemorrhages that endanger the health of patient with acute ITP. Therefore, an individualized dosing regimen should be applied according to patients' morbid condition. A reasonable treatment protocol may get a good efficacy in individual patient.
Side-effects are considered IVIG-related if they happen within 24 h of an infusion [3] . Some studies had reported the side-effect after using the IVIG [9, 10, 12, 13, 18, 21] , such as headache, nausea, vomiting, fever and rash, but most of them were mild and happened to the patients after intravenous administration of HD-IVIG. Increasing the infusion rates in a shorter duration could elevate the frequency of adverse events [32] . It seems that the plasma level of infused IVIG may partly be related to the occurrence of adverse reactions. In our study, the low-IVIG regimen could reduce the adverse effects in clinical administration.
For the analysis of whether there were some patients developing chronic ITP, only three reports described [9, 12, 19] . The difference between low-IVIG group and HD-IVIG group was not statistically significant (P ¼ 0.32). The onset of patients with acute ITP becoming chronic ITP seemed to be independent of the dose of IVIG. However, there is not enough clinical evidence to confirm this at present.
When we performed the subgroup analysis according to age or race, most of the results were similar to those of overall patients. However, the difference of sideeffects between low-IVIG and HD-IVIG in children or adults was not statistically significant, and they were similar to the result of whites. We only recruited a small number of studies into our investigation and it might affect the stabilization of our results. To a certain extent, it was difficult to draw a convincing conclusion from this subgroup analysis of age or race.
In conclusion, administration of low-IVIG may have a similar role as HD-IVIG and can reduce the incidence of side-effects. It should be recommended within clinical practice guidelines and public health policies.
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Limitations
Limitations of our review mainly concern the methodological quality of some recruited studies. Limiting factors include the absence of reporting adverse events and rate of patients developing chronic ITP in most studies. The follow-up was too short in most reports and only three studies [9, 12, 19] had reached 6 months duration. The number of the included investigations was small, and it was difficult to conduct a subgroup analysis according to age or race and draw a convincing conclusion. By composing a funnel plot for the indicator of effective rate, we found there existed publication bias in our study. The conservative assumption we made was that a number of small negative unpublished trials were missed, and our results might be biased toward showing a more positive effect than truly exists. The results of our meta-analysis may be robust on the basis of the fact that they had low statistical heterogeneity. Otherwise, the sample size in some studies was small [11] [12] [13] [14] [15] 19 ] and the quality of methodology used in some reports was poor [10, 11, 13, 15, 16, 20] . To a certain extent, it affected the conviction of our outcome. Publication bias. OR, odds ratio; SE, standard error.
